Paracetamol Infusion Market was valued at USD 699.1 million in 2021 and is expanded to grow at a significant CAGR of 3.86% over 2022-2028. The increased application of paracetamol as a first-line pain and fever reliever propels the global paracetamol infusion market forward.  The National Health Service (NHS), The National Institute for Health and Care Excellence (NICE), and the Centers for Disease Control and Prevention (CDC) have all advised paracetamol because of its broad availability. Initially, the COVID-19 pandemic created a rise in market for over-the-counter medicines like paracetamol, causing local authorities to place export limits on key drugs while maintaining acceptable supply levels in their country. Likewise, the drug's broad use in COVID-19-affected patients to control various symptoms of cold, cough, and fever is projected to boost market expansion. Furthermore, supportive government policies and schemes such as Pharma Vision 2020, the construction of bulk drug parks, and the production linked incentive programme for domestic bulk drug production are likely to generate attractive chances for market growth in the coming years. People suffering from high fevers and aches and pains linked with the flu frequently take paracetamol. Influenza is a problem in tropical areas. The market is growing due to the rising burden of symptomatic conditions and the usage of OTC medications. Following COVID-19, the Indian chemists' association has agreed not to dispense cold, cough, and fever drugs to anyone without a prescription. However, following the epidemic, local market players expanded paracetamol manufacturing and attempts to encourage availability. Amid the pandemic, increased paracetamol production by local market players, as well as steps to stimulate availability, is projected to drive segment growth throughout the forecast period. The application fever and pain segment is expected to hold the most significant market share in the forecasting years. The rising prevalence of pain and fever is expected the drive this segment. Moreover, COVID-19 has led to a positive impact on the global paracetamol infusion market.   Recent Market Developments: In June 2021, Ethypharm has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use.   In May 2022, Sun Pharmaceutical Industries Limited announced that one of its subsidiaries, S.C. Terapia S.A., Romania has acquired the UractivTM portfolio from Fiterman Pharma in Romania.